Oncovita, a Paris, France-based biotechnology company specializing in the development of therapeutic cancer vaccines and prophylactic vaccines, announced the appointment of Dr. Stéphane Altaba as its new Chief Executive Officer.
Stéphane Altaba is an experienced leader with over 25 years of experience in pharmaceutical firms and biotechnology entrepreneurship. He began his career in R&D, particularly in the development of biotechnological processes at Sanofi, before taking on corporate business development roles at Sanofi and Nordic Pharma.
Mr. Altaba subsequently held various senior management positions, including General Manager of Nordic Pharma Spa in Italy, as well as COO and CEO roles in biotechnology companies such as Genomic Vision, LX Repair and RivelaDX. With a background in agricultural engineering, Mr. Altaba holds a Ph.D. in bioproduction and completed a post-doctoral fellowship in Japan. He is graduated from ESCP Business School.
Oncovita is a biotechnology company dedicated to the design and development of novel therapeutic vaccines in oncology and prophylactic vaccines for infectious diseases. Its vaccine candidates are developed using its proprietary MeasovirR technology platform, which enables the modification of the measles vaccine virus genome. It aims to advance its candidates from the preclinical stage through to clinical proof of concept. At the end of 2023, the company was selected as a laureate of the “Innovations in Biotherapies and Bioproduction” call for projects under the Innovation Santé France 2030 plan and received €4.5M in funding as part of the France 2030 investment plan, managed by Bpifrance. In parallel, Oncovita completed a €3.5M fundraising round with private investors.
These two sources of funding, totaling €8M, support the development of its MVdeltaC immunotherapeutic vaccine in oncology.
FinsMEs
15/10/2024